ArticlePloS one2013
Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Patterns of Care and Outcome Analysis of Nasopharyngeal Carcinoma: An Indonesian Single Institution Study.Asian Pacific journal of cancer prevention : APJCP · 2020Trial
- Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.Journal of cancer research and clinical oncology · 2015Trial
- Improved Overall Survival Due to Reduced Waiting Time in Nasopharyngeal Cancer Patients Treated with Chemoradiotherapy in Yogyakarta, Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities.British journal of biomedical science · 2025Review
- Long Non-Coding RNA Small Nucleolar RNA Host Gene 4 Induced by Transcription Factor SP1 Promoted the Progression of Nasopharyngeal Carcinoma Through Modulating microRNA-510-5p/Centromere Protein F Axis.Biochemical genetics · 2023Article
- Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma.Non-coding RNA research · 2022Article
- Article
- Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients.Journal of cancer epidemiology · 2021Article
- In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.Human vaccines & immunotherapeutics · 2019Article
- Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas.Cancers · 2018Article
- The role of Indonesian patients' health behaviors in delaying the diagnosis of nasopharyngeal carcinoma.BMC public health · 2017Article
- Article
- Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia.Osong public health and research perspectives · 2016Article
- Incidence and Mortality of Nasopharynx Cancer and Its Relationship With Human Development Index in the World in 2012.World journal of oncology · 2016Article
- IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker.Oncotarget · 2016Article
- Effectiveness of a multicentre nasopharyngeal carcinoma awareness programme in Indonesia.BMJ open · 2016Article
- The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study.PloS one · 2016Article
- Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.Cell & bioscience · 2016Article
- A prospective study: current problems in radiotherapy for nasopharyngeal carcinoma in yogyakarta, indonesia.PloS one · 2014Article
- The use of biologically related model (Eclipse) for the intensity-modulated radiation therapy planning of nasopharyngeal carcinomas.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNasopharyngeal Carcinoma (NPC) is a major health problem in southern and eastern Asia. In Indonesia NPC is the most frequent cancer in the head and neck area. NPC is very sensitive to radiotherapy resulting in 3-year disease-free and overall survival of approximately 70% and 80%, respectively. Here we present routine treatment results in a prospective study on NPC in a top referral; university hospital in Indonesia.
methodsAll NPC patients presenting from September 2008 till January 2011 at the ear, nose and throat (ENT) department of the Dr. Sardjito General Hospital, Universitas Gadjah Mada, Yogyakarta, Indonesia, were possible candidates. Patients were included if the biopsy was a histological proven NPC without distant metastasis and were assessed during counselling sessions prior to treatment, as being able to complete the entire treatment.
resultsIn total 78 patients were included for treatment analysis. The median time between diagnosis and start of radiotherapy is 120 days. Forty-eight (62%) patients eventually finished all fractions of radiotherapy. The median duration of the radiotherapy is 62 days for 66 Gy. Median overall survival is 21 months (95% CI 18-35) from day of diagnosis.
conclusionThe results presented here reveal that currently the treatment of NPC at an Indonesian hospital is not sufficient and cannot be compared to the treatment results in literature. Main reasons for these poor treatment results are (1) a long waiting time prior to the start of radiotherapy, (2) the extended overall duration of radiotherapy and (3) the advanced stage of disease at presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.